Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trialJean‐Jacques Grob, Caroline Robert, Florent Grange et al.|The Lancet Oncology|2015Cited by 264
Phase 2 study of the IDO/PD-L1-targeted immune-modulatory vaccine, IO102-IO103, plus pembrolizumab as first-line treatment for metastatic non–small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), or urothelial bladder cancer (UBC).Jonathan W. Riess, Ezra E.W. Cohen, Paul Shaw et al.|Journal of Clinical Oncology|2022Cited by 3
756 A phase 2 trial of the IO102-IO103 cancer vaccine plus pembrolizumab: results from the first-line (1L) cohort of PD-L1 high metastatic non-small cell lung cancer (NSCLC)Jonathan W. Riess, Pilar Garrido, James Spicer et al.|Regular and Young Investigator Award Abstracts|2024Cited by 1
3345 COMBI-v: health-related quality of life (HRQoL) impact of the combination of dabrafenib and trametinib (D+T) vs vemurafenib (V) in patients with BRAF V600 metastatic melanoma (MM)Jean‐Jacques Grob, Caroline Robert, Mayur M. Amonkar et al.|European Journal of Cancer|2015Cited by 0